These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30917075)

  • 1. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
    An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
    J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
    Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.
    Shafrin J; Ganguli A; Gonzalez YS; Shim JJ; Seabury SA
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1472-1481. PubMed ID: 27882832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of treatment patterns and healthcare utilization of newly-diagnosed rheumatoid arthritis patients by anti-cyclic citrullinated peptide antibody status.
    Lamerato L; Price K; Szymialis R; Eaddy M; Ogbonnaya A; Shih HC; Ahmad H
    J Med Econ; 2018 Mar; 21(3):231-240. PubMed ID: 29027497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis.
    Harrold LR; Shan Y; Connolly SE; Alemao E; Rebello S; Guo L; Kremer JM
    Curr Med Res Opin; 2020 Feb; 36(2):337-342. PubMed ID: 31612736
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
    Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
    Berendsen MLT; van Maaren MC; Arts EEA; den Broeder AA; Popa CD; Fransen J
    J Rheumatol; 2017 Sep; 44(9):1325-1330. PubMed ID: 28668802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
    Park SH; Han X; Lobo F; Kratochvil D; Patel D
    J Med Econ; 2020 Jun; 23(6):624-630. PubMed ID: 32075453
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.
    Kuller LH; Mackey RH; Walitt BT; Deane KD; Holers VM; Robinson WH; Sokolove J; Chang Y; Liu S; Parks CG; Wright NC; Moreland LW
    Arthritis Rheumatol; 2014 Mar; 66(3):497-507. PubMed ID: 24574208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept.
    Bonafede M; Oko-Osi H; Gharaibeh M; Manjelievskaia J; Lopez-Gonzalez L; Collier DH; Stolshek BS
    J Manag Care Spec Pharm; 2020 Feb; 26(2):211-220. PubMed ID: 31823689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cyclic citrullinated peptide antibodies are associated with radiographic damage but not disease activity in early rheumatoid arthritis diagnosed in 2006-2011.
    Ziegelasch M; Boman A; Martinsson K; Thyberg I; Jacobs C; Nyhäll-Wåhlin BM; Svärd A; Berglin E; Rantapää-Dahlqvist S; Skogh T; Kastbom A
    Scand J Rheumatol; 2020 Nov; 49(6):434-442. PubMed ID: 32856532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.